Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease

Not Applicable

Completed

Conditions: Degenerative Disc Disease

Interventions: Device: ProDisc-L Total Disc Replacement or Charité Artificial Disc
Device: Activ-L Artificial Disc

Registration Number: NCT00589797

Lead Sponsor: Aesculap Implant Systems

Brief Summary: The purpose of this study is to learn whether an investigational device called the Activ-L Artificial Disc is safe and effective in the treatment of degenerative disc disease of the lower (lumbar) spine.

Detailed Description: The objective of this clinical study is to evaluate the safety and effectiveness of the Activ-L Artificial Disc for treatment of single-level degenerative disc disease of the lumbar spine in patients who have been unresponsive to at least six months of prior conservative care. The hypothesis of the study is that the Activ-L Disc is non-inferior to the control (the Charité® Artificial Disc \[DePuy Spine\] or ProDisc-L® Total Disc Replacement \[Synthes Spine\]) with respect to the rate of individual subject success at 24 months. Individual subject success is a composite of effectiveness and safety.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 376

Inclusion Criteria

Age 18 - 60, skeletally mature
Symptomatic DDD with objective evidence of lumbar DDD, with any of the following characteristics by MRI scan:
- instability as defined by ≥ 3mm translation or ≥ 5° angulation.
- osteophyte formation of facet joints or vertebral endplates.
- decreased disc height of >2mm as compared to the adjacent level.
- scarring/thickening of the ligamentum flavum, annulus fibrosis, or facet joint capsule.
- herniated nucleus pulposus.
- facet joint degeneration/changes.
- vacuum phenomenon.
Single level symptomatic disease at L4/L5 or L5/S1.
- six months of unsuccessful conservative treatment
ODI score ≥ 40/100.
Surgical candidate for an anterior approach to the lumbar spine.
Back pain at the operative level only, with or without leg pain.
Back pain VAS score greater than the higher of the two VAS leg pain scores.
VAS back pain score ≥ 40/100 mm.
Willing to return for follow-up visits and sign an Informed Consent and HIPAA Authorization.

Exclusion Criteria

Previous surgery at any lumbar level, except IDET (Intradiscal Electrothermal Annuloplasty), percutaneous nucleoplasty, or microdiscectomy.
Chronic radiculopathy, i.e., subject complaint of unremitting pain with a predominance of leg pain symptoms greater than back pain symptoms extending over a period of at least 1 year.
endplate dimensions smaller than 34.5 mm in medial-lateral and/or 27 mm in the anterior-posterior direction
Evidence of significant, symptomatic disc degeneration at another lumbar level.
Preoperative remaining disc height < 3mm
Myelopathy.
Previous compression or burst fracture at the affected level.
Sequestered herniated nucleus pulposus with migration.
Mid-sagittal stenosis of <8mm (by MRI).
Degenerative or lytic spondylolisthesis > 3mm.
Spondylolysis.
Isthmic spondylolisthesis.
Lumbar scoliosis (> 11 degrees of sagittal plane deformity).
Spinal tumor.
Active systemic infection or infection at the site of surgery.
Facet ankylosis or severe facet degeneration.
Continuing steroid use or prior use for more than 2 months.
History of allergies to any of the device components.
Pregnancy or planning to become pregnant within the next 2 years.
Morbid obesity (BMI >35).
Investigational drug or device use within 30 days.
Osteoporosis or osteopenia
Metabolic bone disease.
Leg pain with migrated sequestrum fragment.
History of rheumatoid arthritis, lupus, or other autoimmune disorder.
Ankylosing spondylitis.
History of HIV/AIDS or hepatitis that precludes surgery.
History of deep vein thrombosis, symptoms of arterial insufficiency, or thromboembolytic disease.
Current or recent history of illicit drug or alcohol abuse, or dependence as defined as the continued use of alcohol despite the development of social, legal, or health problems.
Life expectancy <5 years.
Chemotherapy within past 5 years or any cancer other than non-melanoma skin cancer treated with curative intent within the past 5 years.
Prior nephrectomy.
Abdominal adhesions, endometriosis, inflammatory bowel disease, Crohn's disease, diverticulitis, ulcerative colitis or other abdominal pathology that would preclude abdominal surgical approach.
Insulin-dependent diabetes.
Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, ALS (amyotrophic lateral sclerosis), or multiple sclerosis.
History of Pelvic Inflammatory Disease.
Peritonitis.
Currently in active spinal litigation as a result of medical negligence.
Prisoner.
Psychiatric or cognitive impairment that would interfere with the subject's ability to comply with the study requirements, e.g., Alzheimer's disease.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	ProDisc-L Total Disc Replacement or Charité Artificial Disc	Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
Investigational	Activ-L Artificial Disc	Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.

Primary Outcome Measures

Name	Time	Method
Absence of Serious Device Related Adverse Events	24 months	Percent of subjects demonstrating no device related SAE's at 24 months as per the Clinical Events Committee (CEC)
Overall Success at 24 Months Relative to Baseline	24 months	Measured by absence of treatment failure; absence or serious device related AE; maintenance or improvement of ROM at index level; maintenance or improvement of neurological status; improvement in ODI score.
Range of Motion (ROM) Success	24 months	Percent of subjects demonstrating maintenance or improvement in ROM at 24 months compared to baseline
Neurological Success	24 months	Percent of patients demonstrating maintenance or improvement in combined motor and sensory evaluations at 24 months compared to baseline
Device Success	24 months	Percent of subjects demonstrating no Subsequent Surgical Interventions (SSI's) at the index level (L4-L5 or L5-S1) at 24 months.
ODI Success	24 months	Percent of subjects demonstrating an improvement of greater than or equal to 15 points at 24 months compared to baseline

Secondary Outcome Measures

Name	Time	Method
VAS Success for Back and Leg Pain at Rest	24 months	Number of patients demonstrating improvement in back and leg pain at 24 months compared to baseline
ODI Success Using Two Measures of Success	24 months	Number of subjects demonstrating improvement in two measures of ODI success at 24 months compared to baseline
Improvement in SF-36 Scores	24 months	Number of subjects demonstrating a greater than or equal to 15% improvement in mental (MCS) and physical (PCS) component summary scores at 24 months compared to baseline

Trial Locations

Locations (17): University Hospitals of Cleveland
🇺🇸
Cleveland, Ohio, United States
Aventura Hospital and Medical Center
🇺🇸
Aventura, Florida, United States
Scripps Memorial Hospital La Jolla
🇺🇸
La Jolla, California, United States
University of Colorado Health Sciences Center
🇺🇸
Aurora, Colorado, United States
Yale University School of Medicine/New Haven Hospital
🇺🇸
New Haven, Connecticut, United States
Rancho Specialty Hospital
🇺🇸
Rancho Cucamonga, California, United States
St. John's Hospital and Health Center
🇺🇸
Santa Monica, California, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
University Community Hospital
🇺🇸
Tampa, Florida, United States
Neurosciences Education and Research Foundation
🇺🇸
Peoria, Illinois, United States
Hospital for Special Surgery
🇺🇸
New York, New York, United States
Carolinas Healthcare
🇺🇸
Charlotte, North Carolina, United States
Hamot Medical Center
🇺🇸
Erie, Pennsylvania, United States
Hoag Memorial Hospital Presbyterian
🇺🇸
Newport Beach, California, United States
HealthEast St. John's Hospital
🇺🇸
Maplewood, Minnesota, United States
University of California San Francisco
🇺🇸
San Francisco, California, United States
University of Utah
🇺🇸
Salt Lake City, Utah, United States